Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 8, 2023CellsOpen Access

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCarlo GenovaRTRoberta TassoARAlessandra Rosa

Discussion

Loading...

Member takes

Overview

Cohort study reveals circulating checkpoint proteins predict survival in non-small cell lung cancer, indicating extracellular vesicle involvement in immunotherapy response.

Key Points

  • To evaluate the prognostic significance of soluble and extracellular vesicle-associated immune checkpoint molecules (PD-L1, B7-H3, and B7-H4) in patients with advanced non-small cell lung cancer undergoing immune checkpoint inhibitor therapy.
  • Analyzed baseline and on-treatment blood samples from 126 patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitor treatment.
  • Quantified soluble concentrations and extracellular vesicle expression of PD-L1, B7-H3, and B7-H4, comparing baseline levels to the first radiological assessment.
  • High baseline soluble PD-L1 (>24.2 pg/mL) was associated with worse survival, whereas elevated soluble B7-H3 (>0.5 ng/mL) and soluble B7-H4 (>63.9 pg/mL) correlated with superior outcomes in treatment-naive individuals.
  • Extracellular vesicles expressed PD-L1 and B7-H3 broadly, with patients responding to therapy showing a significant decrease in vesicle-bound PD-L1 and an increase in vesicle-bound B7-H3 at the first radiological assessment.

Cite This Study

Genova et al. (2023) studied this question.

synapsesocial.com/papers/6a0057712ff633f36577e5bdhttps://doi.org/10.3390/cells12060832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Stage-specific embryonic antigen-4is expressed in basaloid lung cancer and associated with poor prognosis2012 · 26 citations
  2. 2Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,641 citations
  3. 3Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum2008 · 199 citations
  4. 4Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer2018 · 6,764 citations
  5. 5Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56<sup>bright</sup>CD16<sup>−</sup> cells and display an impaired capability to kill tumor cells2008 · 369 citations